Drug intelligence / Profile preview

BALI

Development stage: Preclinical
Modality: Small Molecules

Overview

BALI is a substance that mitigates mitochondrial dysfunction and PANoptotic responses, which integrate pyroptosis, apoptosis, and necroptosis. It has been shown to reduce mitochondrial reactive oxygen species (mtROS) and affect cytochrome c, thereby alleviating necroptosis and apoptosis. This action contributes to mitigating conditions like citrinin-induced renal injury.

Targets

CYCS (Cytochrome c)

Beyond the preview

Go deeper on BALI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BALI.

Explore the full profile